Patibandla Srihita, Bhatt Nilay, Lief Sean, Beauti Samer M, Ansari Ali Z
Department of Internal Medicine, Trinity Health Grand Rapids, Grand Rapids, USA.
Department of Internal Medicine, Hospital Corporation of America (HCA) Houston Healthcare Clear Lake, Webster, USA.
Cureus. 2024 Aug 14;16(8):e66875. doi: 10.7759/cureus.66875. eCollection 2024 Aug.
Chronic obstructive pulmonary disease (COPD) represents a significant global health burden, characterized by progressive airflow limitation and exacerbations that significantly impact patient morbidity and mortality. Recent research has investigated the interplay between the gut and the lungs, known as the gut-lung axis, highlighting the role of the gut microbiome in COPD pathogenesis. Dysbiosis, characterized by microbial imbalance, has implications for COPD, influencing disease progression and susceptibility to exacerbations. This comprehensive review integrates current scientific literature on gut microbiota modulation as a therapeutic avenue for COPD management. Through a thorough discussion of studies investigating probiotics, prebiotics, synbiotics, antibiotics, dietary fiber, and fecal microbiota transplantation, this review summarizes the influence of these interventions on COPD via the gut-lung axis through the modulation of systemic inflammation, mucosal immunity, and metabolic processes. The interventions highlighted here show potential in preventing COPD exacerbations, preserving lung function, and improving patient quality of life. By compiling the latest scientific evidence, this review provides a comprehensive framework for physicians and researchers to deduce the effectiveness of gut microbiome modulation as an adjunctive therapeutic strategy in COPD management.
慢性阻塞性肺疾病（COPD）是一项重大的全球健康负担，其特征为进行性气流受限和急性加重，这会显著影响患者的发病率和死亡率。最近的研究探讨了肠道与肺部之间的相互作用，即肠-肺轴，强调了肠道微生物群在COPD发病机制中的作用。以微生物失衡为特征的生态失调与COPD相关，影响疾病进展和急性加重的易感性。这篇综述综合了当前关于调节肠道微生物群作为COPD管理治疗途径的科学文献。通过全面讨论研究益生菌、益生元、合生元、抗生素、膳食纤维和粪便微生物群移植的研究，本综述总结了这些干预措施通过调节全身炎症、粘膜免疫和代谢过程，经由肠-肺轴对COPD的影响。此处强调的干预措施在预防COPD急性加重、维持肺功能和改善患者生活质量方面显示出潜力。通过汇编最新的科学证据，本综述为医生和研究人员提供了一个全面的框架，以推断调节肠道微生物群作为COPD管理辅助治疗策略的有效性。
